NCT03882996View on ClinicalTrials.gov

A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)

PHASE3CompletedINTERVENTIONAL
Enrollment

432

Participants

Timeline

Start Date

October 6, 2000

Primary Completion Date

February 4, 2003

Study Completion Date

February 4, 2003

Conditions
Hypercholesterolemia
Interventions
DRUG

Ezetimibe

Ezetimibe 10 mg daily in the morning

DRUG

Atorvastatin

Atorvastatin 10 mg daily in the morning. Atorvastatin dose could be titrated up (by doubling the dose up to a maximum of 80 mg daily) to achieve the target low-density-lipoprotein cholesterol (LDL-C) level of 100 mg/dL (2.59 mmol/L) after a minimum of 4 weeks of treatment.

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT03882996 - A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032) | Biotech Hunter | Biotech Hunter